Bayer gains first menstrual bleeding indication for oral contraceptive
This article was originally published in Scrip
Executive Summary
Bayer HealthCare Pharmaceuticals became the first company to win an indication in the US for its oral contraceptive Natazia (estradiol valerate and estradiol valerate/dienogest) as a treatment for heavy menstrual bleeding (HMB) not caused by any diagnosed conditions of the uterus in women.